Chromadex Corp
ChromaDex Corporation operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) t… Read more
Chromadex Corp (CDXC) - Total Liabilities
Latest total liabilities as of December 2024: $20.10 Million USD
Based on the latest financial reports, Chromadex Corp (CDXC) has total liabilities worth $20.10 Million USD as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Chromadex Corp - Total Liabilities Trend (2007–2024)
This chart illustrates how Chromadex Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Chromadex Corp Competitors by Total Liabilities
The table below lists competitors of Chromadex Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sino BiologicalInc.
SHE:301047
|
China | CN¥205.26 Million |
|
PSG Corp. PCL
BK:PSG
|
Thailand | ฿702.46 Million |
|
Yan Tai Shuang Ta Food Co Ltd
SHE:002481
|
China | CN¥2.29 Billion |
|
Pansoft Company Limited
SHE:300996
|
China | CN¥169.81 Million |
|
Compass Diversified Holdings
NYSE:CODI
|
USA | $2.47 Billion |
|
Major Drilling Group International Inc
PINK:MJDLF
|
USA | $220.94 Million |
|
Nanjing Canatal Data Centre Environmental Tech Co Ltd Class A
SHG:603912
|
China | CN¥1.74 Billion |
|
Columbus McKinnon Corporation
NASDAQ:CMCO
|
USA | $839.67 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down Chromadex Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chromadex Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chromadex Corp (2007–2024)
The table below shows the annual total liabilities of Chromadex Corp from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $22.18 Million | -16.31% |
| 2023-12-31 | $26.51 Million | +4.42% |
| 2022-12-31 | $25.39 Million | -2.79% |
| 2021-12-31 | $26.11 Million | +19.05% |
| 2020-12-31 | $21.93 Million | +10.77% |
| 2019-12-31 | $19.80 Million | +31.54% |
| 2018-12-31 | $15.05 Million | +69.34% |
| 2017-12-31 | $8.89 Million | -9.08% |
| 2016-12-31 | $9.78 Million | -27.44% |
| 2015-12-31 | $13.47 Million | +77.07% |
| 2014-12-31 | $7.61 Million | +129.11% |
| 2013-12-31 | $3.32 Million | -34.11% |
| 2012-12-31 | $5.04 Million | +35.93% |
| 2011-12-31 | $3.71 Million | +136.04% |
| 2010-12-31 | $1.57 Million | -37.59% |
| 2009-12-31 | $2.52 Million | +7.87% |
| 2008-12-31 | $2.33 Million | +583386.75% |
| 2007-12-31 | $400.00 | -- |